AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results